HealthcareServices

Global Peripheral Neuropathy Market Report 2026–2030: Data-Driven Growth Insights

March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the peripheral neuropathy market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Peripheral Neuropathy Market in 2030?

The peripheral neuropathy market has seen a rapid increase in size over recent years. It is anticipated to expand from $4.59 billion in 2025 to $5.17 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.7%. The expansion observed in the historic period stemmed from factors such as the high prevalence of diabetic neuropathy, rising chemotherapy use, limited targeted therapies, reliance on conventional analgesics, and a lack of early diagnosis tools.

The peripheral neuropathy market is anticipated to experience substantial growth in the upcoming years. It is forecasted to expand to $7.98 billion by 2030, achieving a compound annual growth rate (CAGR) of 11.5%. This expansion during the forecast period can be attributed to advances in nerve stimulation therapies, the rising adoption of physical therapy and non-pharmacological treatments, an increased availability of topical and systemic medications, the growing reliance on online pharmacies and telemedicine, and the expansion of specialized clinics and ambulatory centers. Noteworthy trends for the forecast period include a surge in the adoption of AI-based diagnostic tools for peripheral neuropathy, greater integration of big data and cloud solutions in patient monitoring, the increasing application of genomics and precision medicine for peripheral neuropathy treatment, a wider deployment of IoT-enabled wearable devices for nerve health, and the growing implementation of Industry 4.0 technologies in neuropathy treatment devices.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16507&type=smp

What Drivers Are Influencing Production Trends In The Peripheral Neuropathy Market?

The increasing incidence of diabetes is anticipated to stimulate the expansion of the peripheral neuropathy market moving forward. Diabetes is defined as a chronic condition characterized by elevated glucose levels in the bloodstream, resulting from the body’s impaired capacity to produce or effectively utilize insulin. The escalation in diabetes prevalence is primarily attributed to factors such as rising obesity rates, inactive lifestyles, and an aging population. Diabetes can lead to peripheral neuropathy by causing damage to nerves due to prolonged high blood sugar levels, manifesting as symptoms like pain, tingling, and numbness in the extremities. Effective management of blood sugar is essential to prevent or decelerate the progression of this complication. For instance, in 2024, the International Diabetes Federation, a Belgium-based diabetes research organization, published that the worldwide number of adults aged 20 to 79 years living with diabetes is forecast to grow substantially from around 589 million in 2024 to 853 million by 2050, representing a 45% increase. Consequently, the rising prevalence of diabetes is fueling the growth of the peripheral neuropathy market.

Which Segments Are Gaining Traction In The Peripheral Neuropathy Market?

The peripheral neuropathy market covered in this report is segmented –

1) By Type: Chemotherapy-Induced, Diabetic, Human Immunodeficiency Virus (HIV) Or Acquired Immunodeficiency Syndrome (AIDS Associated), Idiopathic

2) By Diagnosis: Blood Test, Biopsy, Imaging, Other Diagnosis

3) By Treatment: Medications, Antidepressants, Anti-Seizure Medication, Pain Reliever, Topical Treatment, Therapies, Nerve Stimulation, Plasma Exchange, Physical Therapy, Other Treatments

4) By End-User: Hospitals, Clinics, Ambulatory Centers

Subsegments:

1) By Chemotherapy-Induced: Taxane-Induced Peripheral Neuropathy, Platinum-Based Drug-Induced Neuropathy, Other Chemotherapy-Induced Neuropathies

2) By Diabetic: Type 1 Diabetes-Induced Peripheral Neuropathy, Type 2 Diabetes-Induced Peripheral Neuropathy

3) By Human Immunodeficiency Virus (HIV) Or Acquired Immunodeficiency Syndrome (AIDS) Associated: HIV-Associated Peripheral Neuropathy, AIDS-Related Peripheral Neuropathy

4) By Idiopathic: Acute Idiopathic Neuropathy, Chronic Idiopathic Neuropathy

What Trends Are Projected To Support The Growth Of The Peripheral Neuropathy Market?

Major companies operating in the peripheral neuropathy market are concentrating on developing advanced solutions, such as point-of-care devices, to enhance the diagnosis and management of the condition. A point-of-care peripheral neuropathy quantitative screening test functions as a diagnostic instrument utilized for the rapid detection of nerve damage in the extremities of individuals, particularly those with diabetes. For instance, in January 2023, NeuroMetrix Inc., a US-based non-invasive medical device manufacturer, unveiled the DPNCheck 2.0 point-of-care device specifically for identifying peripheral neuropathy. This device leverages nerve conduction technology to pinpoint the systemic degeneration of peripheral nerves, which can lead to debilitating conditions like diabetic peripheral neuropathy (DPN). It enables rapid patient screening through quantitative measurement of peripheral nerve function, establishing it as a more efficient and accurate tool compared to traditional methods such as monofilament and tuning fork tests.

Who Are The Primary Competitors In The Global Peripheral Neuropathy Market?

Major companies operating in the peripheral neuropathy market are Pfizer Inc., Merck and Co. Inc., Novartis AG, Bristol Myers Squibb Co, AstraZeneca Plc, Abbott Laboratories, Eli Lilly and Co., Daiichi Sankyo Co. Ltd., Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Cadila Pharmaceuticals Ltd., Dr. Reddy’s Laboratories, Cipla Ltd., Apotex Inc, Hikma Pharmaceuticals PLC, Lupin Limited, Grunenthal GmbH, Lexicon Pharmaceuticals, Johnson and Johnson, Teva Pharmaceutical Industries Ltd, Sanofi, GSK plc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Peripheral Neuropathy Market?

North America was the largest region in the peripheral neuropathy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peripheral neuropathy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Peripheral Neuropathy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16507&type=smp

Browse Through More Reports Similar to the Global Peripheral Neuropathy Market 2026, By The Business Research Company

Chemotherapy Induced Peripheral Neuropathy Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-peripheral-neuropathy-treatment-global-market-report

Diabetic Neuropathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report

Peripheral Nerve Injuries Market Report 2026

https://www.thebusinessresearchcompany.com/report/peripheral-nerve-injuries-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795